Get the lowdown on lipids!
Expand your knowledge of lipid sources used in
PN in this brief video.
See how Fresenius Kabi Nutrition may help your critically and chronically ill patients flourish with its portfolio of clinical nutrition products.
We’re proud to support marine conservation by ensuring that the fish oil in our products is sustainably sourced.
Expand your knowledge of lipid sources used in
PN in this brief video.
The first and only four-oil lipid emulsion for adults in the United States.
With SMOFlipid, Fresenius Kabi answered the call from parenteral nutrition (PN) and critical care medical societies for an alternative to soy-based lipid injectable emulsions. This blend of soybean oil, medium-chain triglycerides, olive oil, and fish oil is the FIRST and ONLY advancement in U.S. lipid emulsions for adults in more than 40 years.
Limitations of Use:
The omega-6: omega-3 fatty acid ratio and Medium Chain Triglycerides in SMOFlipid have not been shown to improve clinical outcomes compared to other intravenous lipid emulsions.
The first and only fish oil lipid emulsion for pediatric patients with parenteral nutrition-associated cholestasis (PNAC) in the U.S.1
Omegaven is a PN product rich in omega-3s that became commercially available for pediatric patients in November of 2018; Omegaven was previously available only for compassionate care. Fresenius Kabi was aware of the need for this product to be more broadly available to pediatric patients and worked hard to secure the necessary clinical evidence to support FDA approval.
The first and only three-chamber bag for PN.
Kabiven/Perikabiven’s unique design streamlines the delivery of nutrition therapy to patients by simplifying calculations, prescription writing, compounding, and administration, all while supporting PN safety by minimizing the risk of contamination.1 The Kabiven and Perikabiven three-chamber PN bags efficiently deliver three macronutrients (dextrose, protein, and lipids) plus electrolytes in volumes and concentrations that meet the needs of most PN patients.2,3
Important safety information>
Kabiven: Full prescribing information>
Perkabiven: Full prescribing information>
Fresenius Kabi offers an industry standard patient support program, KabiCare. Claims appeals and billing and coding support resources for Parenteral Nutrition are available for your eligible patients.
Angling for more information about fish oil and omega-3s in PN?
SMOFLIPID (lipid injectable emulsion), for intravenous use
BRIEF SUMMARY OF PRESCRIBING INFORMATION
This brief summary does not include all the information needed to use SMOFlipid safely and effectively. Please see full prescribing information, including Boxed Warning for SMOFlipid (lipid injectable emulsion), for intravenous use at www.freseniuskabinutrition.com.
WARNING: DEATH IN PRETERM INFANTS
INDICATIONS AND USAGE
SMOFlipid is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Limitations of Use:
The omega-6: omega-3 fatty acid ratio and Medium Chain Triglycerides in SMOFlipid have not been shown to improve clinical outcomes compared to other intravenous lipid emulsions.
Omegaven (fish oil triglycerides) injectable emulsion, for intravenous use
BRIEF SUMMARY OF PRESCRIBING INFORMATION
This brief summary does not include all the information needed to use Omegaven safely and effectively. Please see full prescribing information for Omegaven (fish oil triglycerides) injectable emulsion for intravenous use at www.freseniuskabinutrition.com.
INDICATIONS AND USAGE
Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).
Limitations of Use:
Omegaven is not indicated for the prevention of PNAC. It has not been demonstrated that Omegaven prevents PNAC in parenteral nutrition (PN)-dependent patients.
It has not been demonstrated that the clinical outcomes observed in patients treated with Omegaven are a result of the omega-6: omega-3 fatty acid ratio of the product.
KABIVEN® (Amino Acids, Electrolytes, Dextrose, and Lipid Injectable Emulsion), for intravenous use
PERIKABIVEN® (Amino Acids, Electrolytes, Dextrose, and Lipid Injectable Emulsion), for intravenous use
BRIEF SUMMARY OF PRESCRIBING INFORMATION
This brief summary does not include all the information needed to use KABIVEN and PERIKABIVEN safely and effectively. Please see full prescribing information, including Boxed Warning for KABIVEN® (Amino Acids, Electrolytes, Dextrose, and Lipid Injectable Emulsion), for intravenous use and PERIKABIVEN® (Amino Acids, Electrolytes, Dextrose, and Lipid Injectable Emulsion), for intravenous use at www.freseniuskabinutrition.com/products/kabiven-perikabiven/.
INDICATIONS AND USAGE
KABIVEN and PERIKABIVEN are each indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. KABIVEN and PERIKABIVEN may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients.
Limitations of Use:
Neither KABIVEN nor PERIKABIVEN is recommended for use in pediatric patients < 2 years including preterm infants because the fixed content of the formulation does not meet nutritional requirements in this age group.
SMOFLIPID (lipid injectable emulsion), for intravenous use
BRIEF SUMMARY OF PRESCRIBING INFORMATION
This brief summary does not include all the information needed to use SMOFlipid safely and effectively. Please see full prescribing information, including Boxed Warning for SMOFlipid (lipid injectable emulsion), for intravenous use at www.freseniuskabinutrition.com.
WARNING: DEATH IN PRETERM INFANTS
INDICATIONS AND USAGE
SMOFlipid is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Limitations of Use:
The omega-6: omega-3 fatty acid ratio and Medium Chain Triglycerides in SMOFlipid have not been shown to improve clinical outcomes compared to other intravenous lipid emulsions.
Omegaven (fish oil triglycerides) injectable emulsion, for intravenous use
BRIEF SUMMARY OF PRESCRIBING INFORMATION
This brief summary does not include all the information needed to use Omegaven safely and effectively. Please see full prescribing information for Omegaven (fish oil triglycerides) injectable emulsion for intravenous use at www.freseniuskabinutrition.com.
INDICATIONS AND USAGE
Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).
Limitations of Use:
Omegaven is not indicated for the prevention of PNAC. It has not been demonstrated that Omegaven prevents PNAC in parenteral nutrition (PN)-dependent patients.
It has not been demonstrated that the clinical outcomes observed in patients treated with Omegaven are a result of the omega-6: omega-3 fatty acid ratio of the product.
KABIVEN® (Amino Acids, Electrolytes, Dextrose, and Lipid Injectable Emulsion), for intravenous use
PERIKABIVEN® (Amino Acids, Electrolytes, Dextrose, and Lipid Injectable Emulsion), for intravenous use
BRIEF SUMMARY OF PRESCRIBING INFORMATION
This brief summary does not include all the information needed to use KABIVEN and PERIKABIVEN safely and effectively. Please see full prescribing information, including Boxed Warning for KABIVEN® (Amino Acids, Electrolytes, Dextrose, and Lipid Injectable Emulsion), for intravenous use and PERIKABIVEN® (Amino Acids, Electrolytes, Dextrose, and Lipid Injectable Emulsion), for intravenous use at www.freseniuskabinutrition.com/products/kabiven-perikabiven/.
INDICATIONS AND USAGE
KABIVEN and PERIKABIVEN are each indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. KABIVEN and PERIKABIVEN may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients.
Limitations of Use:
Neither KABIVEN nor PERIKABIVEN is recommended for use in pediatric patients < 2 years including preterm infants because the fixed content of the formulation does not meet nutritional requirements in this age group.
SMOFlipid References:
1. Klek S, et al. Four-week parenteral nutrition using a third-generation lipid emulsion (SMOFlipid): a double-blind, randomised, multicentre study in adults. Clin Nutr. 2013;32(2):224-231. 2. Mertes N, et al. Safety and efficacy of a new parenteral lipid emulsion (SMOFlipid) in surgical patients: a randomized, double-blind, multicenter study. Ann Nutr Metab. 2006;50(3):253-259. 3. Grimble RH. Fatty acid profile of modern lipid emulsions: scientific consideration for creating the ideal composition. Clin Nutr Suppl. 2005;1(3):9-15. 4. Waitzberg DL, et al. New parenteral lipid emulsions for clinical use. JPEN J Parenter Enteral Nutr. 2006;30(4):351-367. 5. Mayer K, et al. Fish oil in the critically ill: from experimental to clinical data. Curr Opin Clin Nutr Metab Care. 2006;9(2):140-148. 6. Grimm H, et al. Immunonutrition-supplementary amino acids and fatty acids ameliorate immune deficiency in critically ill patients. Arch Surg. 2001;386(5):369-376.
Omegaven Reference:
1. Omegaven Prescribing Information, Fresenius Kabi USA, LLC. 2020.
Kabiven/Perikabiven References:
1. Derenski K. Standardize parenteral nutrition using commercial premix. Pharm Purchasing Prod. 2012;1-7. 2. Kabiven Prescribing Information, Fresenius Kabi USA, LLC. 2016. 3. Perikabiven Prescribing Information, Fresenius Kabi USA, LLC. 2016.